Breaking News, Collaborations & Alliances

GeneQuine Contracts Exothera to Support the Development of Its Osteoarthritis Gene Therapy

GQ-303, the gene therapy candidate, turns joint cells into factories for production of the therapeutic protein proteoglycan 4.

Author Image

By: Charlie Sternberg

Associate Editor

GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to conduct a feasibility study for the development of a large-scale manufacturing process for its osteoarthritis gene therapy product candidate GQ-303 in the highly scalable scale-X fixed-bed bioreactor.   GeneQuine is developing GQ-303, its intraarticular gene therapy c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters